<DOC>
	<DOC>NCT01291199</DOC>
	<brief_summary>The purpose of this study is to determine whether vardenafil is effective in improving clinical symptoms and peripheral blood flow in patients with primary and secondary Raynaud phenomenon.</brief_summary>
	<brief_title>Effects of Vardenafil on Clinical Symptoms and Peripheral Blood Flow in Patients With Raynaud's Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Raynaud Disease</mesh_term>
	<mesh_term>Phosphodiesterase 5 Inhibitors</mesh_term>
	<mesh_term>Vardenafil Dihydrochloride</mesh_term>
	<criteria>raynaudsyndrome (primary or secondary) &gt; 1 year duration age ≥ 18 years; ≤ 80 years informed consent a negative pregnancy test in women of childbearing age any unstable organic, psychiatric or addictive disease, which in the opinion of the investigators might result in an unsuccessful / unreliable participation or premature termination of the trial known contraindications against PDE 5inhibitors (such as intolerance, therapy with nitrates or inhibitors of CYP3A4, etc.) extensive necrosis of the finger tips pigmentary retinopathy verification as a HbsAg or hepatitis C carrier unstable angina heart failure (NYHA III or IV) valve defects of higher degree (particularly aortic stenosis and hypertrophic obstructive cardiomyopathy) myocardial infarction, stroke or lifethreatening cardiac arrhythmias within the last 6 months uncontrolled atrial fibrillation / flutter with a heart rate &gt; 100 bpm prolonged QTcinterval (&gt; 450 msec) congenital longQTsyndrome hypokalemia severe acute or chronic liver disease, which might lead to priapism (sickle cell anemia, leucemia) hemophilia active peptic ulcers arterial hypotension (systolic blood pressure at rest &lt;90 mmHg) or arterial hypertension(systolic blood pressure at rest &gt;170 mmHg or diastolic blood pressure at rest &gt;110 mmHg) malignancy within the last 5 years (except squamous or basal cell skin cancer) patients with injuries of the spinal cord or central nervous system patients with severe chronic kidney disease (creatinin clearance &lt; 30 ml) patients with mild to severe liver disease (ChildPugh AC) Age below 18 or above 80 prohibited concomitant medication during the study: nitrates or other NOdonators (including amylnitrit) anticoagulative drugs except inhibitors of thrombocyte function androgens (such as testosterone) or antiandrogens strong inhibitors of cytochrome P4503A4: very potent HIVProteaseinhibitors (ritonavir, indinavir) antimycotic like itraconazole and ketoconazole (topical applications are allowed) erythromycin grapefruitjuice or products containing grapefruitjuice other study medications (including placebo) up to 30 days before study inclusion therapy of erectile dysfunction(including sildenafil, sublingual apomorphin, MUSE®, intracavernous injections or vacuum pumps) or other therapies of erectile dysfunction within 4 weeks and during the trial period nebivolol alphablockers Calcium antagonists medications prolonging the QTinterval abnormal lab tests like: serumcreatinine &gt; 3 mg/dl at visit 1 GOT and GPT &gt; 3 x reference limit set diabetes mellitus with a HbA1c &gt; 9% patients who are not willing to disclaim a therapy of their erectile dysfunction with vacuum pumps, intravenous injections, sildenafil or other therapies during the trial severe migraine (more than once a moth during the last 6 months) intolerance to the study medication patients who are not able to understand the information and informed consent due to a mental disorder or linguistic barriers persons who are living in a institution directly under federal government control due to a court order patients who refuse to renounce drinking grapefruit juice during the trial women who are pregnant or lactating women who are not protected from a pregnancy (intake of oral contraceptives alone in insufficient; highly effective methods of birth control have to be used with a failure rate &lt;1%; barriers: implants, intrauterinedevices (IUD´s),diaphragm, condoms, abstinence, partner is vasectomized, spermicides) patients who participated in other interventional studies within 30 days of study inclusion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>double-blind placebo controlled cross-over study</keyword>
</DOC>